| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 29, 2017A subgroup analysis of data from the Phase III COMPACT trial showed 98 percent median reduction in hereditary angioedema (HAE) attacks per month in subjects who experienced at least one attack per week while on placebo
29 Oct 2017 KING OF PRUSSIA, Pa. — 29 October 2017 Global biotherapeutics leader CSL Behring today presented data indicating that, at the approved dose of 60 IU/kg, HAEGARDA® reduced the median...
-
Oct 24, 2017- HAEGARDA is the first and only subcutaneous preventive treatment option for HAE in the US - Oral presentation will highlight the preventive effect of HAEGARDA in HAE patients with a high frequency of attacks
24 Oct 2017 KING OF PRUSSIA, Pa — 24 October 2017 Global biotherapeutics leader CSL Behring announced today that new data will be presented for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous...
-
Oct 12, 2017There are more than 350,000 cardiac arrests annually in the U.S.; nearly 90 percent are fatal but when CPR is administered immediately, chances of survival can triple.
12 Oct 2017 KING OF PRUSSIA, Pa. — 12 October 2017 CSL Behring is taking its workplace wellness initiatives to a whole new level by providing the American Heart Association’s (AHA)...
-
Sep 28, 2017AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat hemophilia A
28 Sep 2017 TOKYO — 28 September 2017 AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A AFSTYLA® reduces the number of injections...
-
Sep 28, 2017CSL Behring’s LEAD grant is helping them advocate more effectively in a shifting health care environment.
28 Sep 2017 KING OF PRUSSIA, Pa. — 28 September 2017 The Great Lakes Hemophilia Foundation (GLHF) headquartered in Milwaukee, Wis., the New York City Hemophilia Chapter (NYCHC) and the Ohio...
-
Sep 19, 2017CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn StateCSL Behring commits $4.92 million to Penn State's multidisciplinary Center of Excellence in Biotechnology
19 Sep 2017 UNIVERSITY PARK, Pa. — 19 September 2017 Penn State today announced that CSL Behring a global specialty biotherapeutics leader, has committed $4.92 million to Penn State over the...
-
Sep 14, 2017Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives
14 Sep 2017 EDINBURGH, UK — 14 September 2017 Global biotherapeutics leader CSL Behring today announced that its “Join Together” campaign at the 2017 European Society for Immunodeficiencies...
-
Sep 14, 2017Privigen shown to improve functional abilities in patients with a rare neurological condition
14 Sep 2017 KING OF PRUSSIA, Pa. — 14 September 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune...
-
Sep 7, 2017- Symposium “Transitioning Clinical Data into Patient Care – Recent Real-Life Experiences with Alpha 1” - RAPID and RAPID extension trial data to be featured in poster and oral presentations
07 Sep 2017 MARBURG, Germany — 07 September 2017 Global biotherapeutics leader CSL Behring will host a symposium about Alpha 1 Antitrypsin Deficiency (AATD) on Monday, 11 September, during the...
-
Sep 6, 2017Biotherapeutics leader to map attendee visits to result in a donation to International Patient Organisation for Primary Immunodeficiencies (IPOPI)
06 Sep 2017 EDINBURGH, Scotland — 06 September 2017 Global biotherapeutics leader CSL Behring today announced that as part of its participation as a platinum sponsor of the 2017 meeting of the...
-
Jul 25, 2017- First and only subcutaneous preventive treatment option reduced HAE attacks by 95 percent (median) in treated patients - Comprehensive support program offered to patients
25 Jul 2017 KING OF PRUSSIA, Pa. — 25 July 2017 Global biotherapeutics leader CSL Behring today announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in...
-
Jul 21, 2017FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks
21 Jul 2017 KING OF PRUSSIA, Pa. — 21 July 2017 Global biotherapeutics leader CSL Behring today announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven...
-
Jul 19, 2017For the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
19 Jul 2017 KING OF PRUSSIA, Pa. — 19 July 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s...
-
Jul 12, 2017Findings presented at the International Society on Thrombosis and Haemostasis Congress 2017 show product’s impact on treatment adherence, consumption and quality of life
12 Jul 2017 BERLIN — 12 July 2017 CSL Behring today presented data finding that prophylaxis treatment with IDELVION® provides consistently high factor IX levels, resulting in low bleeding rates...
-
Jul 11, 2017CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards
11 Jul 2017 SITGES, Spain — 11 July 2017 Global biotherapeutics leader CSL Behring today announced at the Peripheral Nerve Society’s annual meeting the winners of its annual Interlaken...
-
Jul 10, 2017Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017
10 Jul 2017 BERLIN — 10 July 2017 CSL Behring today presented data finding treatment with AFSTYLA® may result in low average product consumption without compromising efficacy in both the...
-
Jul 6, 2017New findings demonstrate CSL Behring’s promise to develop and deliver innovative treatments that improve patients’ lives
06 Jul 2017 MARBURG, Germany. — 06 July 2017 CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the International Society...
-
Jun 23, 2017- HAEGARDA has been shown to reduce HAE attacks by 95 percent (median) in patients with a life-threatening, rare genetic disorder - Use of rescue medication was reduced by greater than 99 percent (1) - Subcutaneous administration builds and maintains steady-state C1-INH levels
23 Jun 2017 KING OF PRUSSIA, Pa. — 23 June 2017 Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved HAEGARDA® (C1 Esterase...
-
May 19, 2017Driven by its promise to save lives and protect people’s health, CSL Behring is honoured to be recognized by NORD, a tireless advocate for rare disease patients.
19 May 2017 KING OF PRUSSIA, Pa. — 19 May 2017 CSL Behring received the National Organization for Rare Disorders’ (NORD) 2017 Industry Innovation Award last night in Washington, D.C. for...
-
Apr 19, 2017- AFSTYLA is the first and only single-chain recombinant factor VIII product to treat haemophilia A.
19 Apr 2017 MELBOURNE, Australia — 19 April 2017 AFSTYLA is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A AFSTYLA reduces the number of...
-
Apr 10, 2017CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).
10 Apr 2017 MONTREAL and KING OF PRUSSIA, Pa. — 10 April 2017 CSL Behring Marks World Hemophilia Day by Donating IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia...
-
Mar 31, 2017CSL Behring Sponsors the First Network of its Kind on the African Continent
31 Mar 2017 LIVINGSTONE, ZAMBIA — 31 March 2017 Global biotherapeutics leader CSL Behring today announced its commitment to sponsor the Jeffrey Modell North African Network, which will establish...
-
Mar 29, 2017CSL Behring’s Local Empowerment for Advocacy Development Grant helps rare disease patient groups and patients protect access to lifesaving therapies.
29 Mar 2017 KING OF PRUSSIA, Pa — 29 March 2017 Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD)...
-
Mar 22, 2017The New England Journal of Medicine published data from the COMPACT study which demonstrated the safety and efficacy of CSL830 to prevent HAE attacks.
22 Mar 2017 KING OF PRUSSIA, Pa — 22 March 2017 Median reduction in hereditary angioedema (HAE) attack rate relative to placebo was 95% at the highest dose studied Data show up to 40% of HAE...
-
Mar 1, 2017PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy
01 Mar 2017 KING OF PRUSSIA, Pa — 01 March 2017 Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy...